HALF YEAR RESULTS Double-digit revenue growth EBITDA profit

Paris, France and Camberley, UK – 26 September 2019 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces unaudited results for the six months ended 30 June 2019. http://novacyt.com/wp-content/uploads/2019/09/Novacyt-half-year-2019-results-PR-25-9-19-FINAL-ENGLISH.pdf

Visit Page

Conversion d’OCABSA

Paris, France et Camberley, UK – 25 septembre 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste international du diagnostic Clinique, annonce qu’en vertu du Programme de Financement par Obligations Convertibles assorties de Warrants annoncé le 26 avril 2019, elle a émis une tranche d’actions ordinaires nouvelles de 1/15 € chacune (« Actions Ordinaires »)

Visit Page

Conversion of Loan Notes

Paris, France and Camberley, UK – 25 September 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme announced on 26 April 2019, it has issued a tranche of new ordinary shares of €1/15 each (“Ordinary Shares”) to Negma Group

Visit Page